A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs GSK 2646264 (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 19 Jan 2017 Planned primary completion date changed from 1 May 2018 to 1 Jun 2018.
- 19 Jan 2017 Status changed from not yet recruiting to recruiting.
- 12 Jan 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.